February 14, 2023
Primary Results from the Randomized PHASE II RIGHT Choice Trial of Premenopausal Patients with Aggressive HR+/HER 2 Neu- Advanced Brest Cancer Treated with Ribociclib Endocrine Therapy versus Treatment of Physicians Choice Combination Chemotherapy.